• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is It Worth Adding Coenzyme Q10 to Atomoxetine for ADHD?
Research Update

Is It Worth Adding Coenzyme Q10 to Atomoxetine for ADHD?

April 1, 2023
Dorothy Chyung, MD
From The Carlat Child Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Dorothy Chyung, MD. Dr. Chyung has no financial relationships with companies related to this material.

REVIEW OF: Gamal F et al, CNS Neurol Disord Drug Targets 2022;21(8):717–723

STUDY TYPE: Randomized, double-blind, placebo-controlled trial

Many supplements have been touted to help ADHD. The pathophysiology of this disorder may be associated with oxidative stress, so it is reasonable to consider an antioxidant intervention (Joseph N et al, J Atten Disord 2013;19(11):915–924). In this study, researchers tested whether augmentation of atomoxetine with the antioxidant coenzyme Q10 would further improve ADHD symptoms.

Researchers recruited 60 children ages 6–16 years who continued to have ADHD symptoms despite taking atomoxetine for six months. Half received placebo and the other half received coenzyme Q10 (1–3 mg/kg/day). Serum levels were not checked in this study; however, the dosage range came from a pediatric migraine study that showed increased coenzyme Q10 serum levels from a mean of 0.6 μg/mL to 1.2 μg/mL (Hershey AD et al, Headache 2007;47(1):73–80). ADHD symptoms were measured with the Conners Parent Rating Scale-48 before and after one, three, and six months of treatment. There was no industry funding for this study.

The addition of coenzyme Q10 yielded a 16% greater improvement than placebo in ADHD hyperactivity, impulsivity, and learning problems after six months of treatment. Adverse effects included nausea; however, there was no statistically significant difference in adverse effects between the groups.

Since this study was conducted in Egypt, where stimulants are not widely available, the patient population may be different than in the US, where many people are prescribed atomoxetine if they are unable to tolerate stimulants.

Carlat Take

There is not yet enough evidence to recommend coenzyme Q10 as a standard treatment for ADHD. However, many patients with ADHD do not tolerate stimulant medication or get only partial benefit from atomoxetine or alpha-agonists. For children who continue to struggle with hyperactivity, impulsivity, and learning despite optimizing existing treatments, we can add coenzyme Q10 to our list of understudied, probably harmless, and possibly helpful adjunctive supplements to try.

Child Psychiatry Research Update
KEYWORDS ADHD adjunct-treatment atomoxetine attention deficit hyperactivity disorder co-enzyme Q10 Co-Q10
    Dorothy Chyung, MD

    Ziprasidone for Mania in Bipolar I Disorder in Children and Teens

    More from this author
    www.thecarlatreport.com
    Issue Date: April 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Autism in Children and Adolescents, CCPR, April/May/June 2023
    Treating Irritability in Autism: Functional and Medication Approaches
    Addressing Suicidality in Autistic Children and Teens
    Recognizing and Treating Psychosis in Autism
    Autistic Drivers Perform Well
    Testing Neurofeedback for ADHD
    Is It Worth Adding Coenzyme Q10 to Atomoxetine for ADHD?
    Does Treatment of ADHD Help Caregiver Stress?
    Stimulant Treatment Effect on Anxiety in ADHD
    Why Do So Many Pediatric Antidepressant Research Trials “Fail”?
    CME Post-Test, Autism in Children and Adolescents, CCPR, April/May/June 2023
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.